Trials / Completed
CompletedNCT00140049
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 238 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon \& 4 PM during a 12 week treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalacom | |
| DRUG | Cosopt |
Timeline
- Start date
- 2005-07-01
- Completion
- 2006-07-01
- First posted
- 2005-08-31
- Last updated
- 2021-02-18
Locations
25 sites across 5 countries: France, Germany, Greece, Italy, Sweden
Source: ClinicalTrials.gov record NCT00140049. Inclusion in this directory is not an endorsement.